Literature DB >> 9665473

Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat.

S M Ho1, I Leav, S Ghatak, F Merk, V S Jagannathan, K Mallery.   

Abstract

Although the functional role of TRPM-2/clusterin in the prostate remains controversial, it has been postulated that transcriptional activation of the gene is an important mechanism in castration-induced prostatic involution and perhaps is a means for prostatic cells to escape apoptotic induction. In the present study, we have measured expression levels of TRPM-2/clusterin and apoptotic activities in the prostates of castrated Noble (NBL) rats and those treated with testosterone (T) and estradiol-17beta (E2) for 16 weeks. We have previously shown that the combined sex hormone treatment (T+E2) induces dysplasia, a purported preneoplastic lesion, exclusively in the dorsolateral prostates (DLPs) of all treated rats. In the present study, we demonstrate that, as expected, castration readily induced enhanced TRPM-2/clusterin expression, which was accompanied by increased apoptotic activity in the epithelia of DLP and ventral prostate (VP). The increase in TRPM-2/clusterin expression appeared earlier and was more dramatic in the VP than in the DLP. In sharp contrast, treatment of rats with T+E2 for 16 weeks induced augmentation of TRPM-2/clusterin expression selectively in the dysplastic lesions of the DLP but not in the lesion-free VP. The enhanced expression of TRPM-2/clusterin in the dysplastic epithelium was, however, not attended by an increase in apoptotic activity within the lesion. Thus, the observed up-regulation of TRPM-2/clusterin expression in the dysplastic foci of T+E2-treated rats occurred in animals whose androgen status remained normal and, despite the increased level of expression of this gene, apoptotic activity in these lesions was unchanged from basal values measured in the DLPs of untreated rats. These findings suggest that TRPM-2/clusterin expression in dysplastic lesions was no longer repressed by androgen nor was it associated with apoptosis. We propose that overexpression of the gene is likely a phenotype of neoplastic transformation. In addition, we speculate that TRPM-2/clusterin may serve as a survival factor, which could favor accumulation of transformed cells in dysplastic foci and thus promote the carcinogenic process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665473      PMCID: PMC1852960          DOI: 10.1016/S0002-9440(10)65553-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.

Authors:  C Magi-Galluzzi; R Mishra; M Fiorentino; R Montironi; H Yao; P Capodieci; K Wishnow; I Kaplan; P J Stork; M Loda
Journal:  Lab Invest       Date:  1997-01       Impact factor: 5.662

2.  Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castration.

Authors:  P P Banerjee; S Banerjee; K I Tilly; J L Tilly; T R Brown; B R Zirkin
Journal:  Endocrinology       Date:  1995-10       Impact factor: 4.736

3.  Bcl-XL protects cancer cells from p53-mediated apoptosis.

Authors:  A F Schott; I J Apel; G Nuñez; M F Clarke
Journal:  Oncogene       Date:  1995-10-05       Impact factor: 9.867

4.  Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin).

Authors:  J A Sensibar; D M Sutkowski; A Raffo; R Buttyan; M D Griswold; S R Sylvester; J M Kozlowski; C Lee
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

5.  Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.

Authors:  A Brändström; P Westin; A Bergh; S Cajander; J E Damber
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

6.  Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity.

Authors:  M Marinelli; D Quaglino; S Bettuzzi; P Strocchi; P Davalli; A Corti
Journal:  Biochem Cell Biol       Date:  1994 Nov-Dec       Impact factor: 3.626

7.  Expression of clusterin in cell differentiation and cell death.

Authors:  H S Ahuja; M Tenniswood; R Lockshin; Z F Zakeri
Journal:  Biochem Cell Biol       Date:  1994 Nov-Dec       Impact factor: 3.626

8.  Apoptosis in decidual tissue regression and reorganization.

Authors:  Y Gu; G M Jow; B C Moulton; C Lee; J A Sensibar; O K Park-Sarge; T J Chen; G Gibori
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

9.  Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.

Authors:  M C Bosland; H Ford; L Horton
Journal:  Carcinogenesis       Date:  1995-06       Impact factor: 4.944

10.  The lurcher gene induces apoptotic death in cerebellar Purkinje cells.

Authors:  D J Norman; L Feng; S S Cheng; J Gubbay; E Chan; N Heintz
Journal:  Development       Date:  1995-04       Impact factor: 6.868

View more
  8 in total

1.  Overexpression of clusterin in human breast carcinoma.

Authors:  M Redondo; E Villar; J Torres-Muñoz; T Tellez; M Morell; C K Petito
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 3.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 4.  Estrogens and prostate cancer: etiology, mediators, prevention, and management.

Authors:  Shuk-Mei Ho; Ming-Tsung Lee; Hung-Ming Lam; Yuet-Kin Leung
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-07       Impact factor: 4.741

Review 5.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin Gleave; Hideaki Miyake
Journal:  World J Urol       Date:  2005-01-26       Impact factor: 4.226

Review 6.  Mechanisms of the development of androgen independence in prostate cancer.

Authors:  Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Journal:  World J Urol       Date:  2005-01-27       Impact factor: 4.226

7.  Clusterin silencing sensitizes pancreatic cancer MIA-PaCa-2 cells to gmcitabine via regulation of NF-kB/Bcl-2 signaling.

Authors:  Miao Xu; Xiumei Chen; Yanling Han; Chunqing Ma; Lin Ma; Shirong Li
Journal:  Int J Clin Exp Med       Date:  2015-08-15

8.  Tracking Prostate Carcinogenesis over Time through Urine Proteome Profiling in an Animal Model: An Exploratory Approach.

Authors:  Alexandra Moreira-Pais; Rita Nogueira-Ferreira; Stephanie Reis; Susana Aveiro; António Barros; Tânia Melo; Bárbara Matos; José Alberto Duarte; Fernanda Seixas; Pedro Domingues; Francisco Amado; Margarida Fardilha; Paula A Oliveira; Rita Ferreira; Rui Vitorino
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.